Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kensey Nash Reviewing TriActiv Distal Protection Marketing Options

This article was originally published in The Gray Sheet

Executive Summary

Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says

You may also be interested in...



Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control

Kensey Nash's TriActiv distal protection system for saphenous vein graft interventions is associated with significantly more in-hospital hemorrhagic/vascular events than controls in the firm's PRIDE trial

Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control

Kensey Nash's TriActiv distal protection system for saphenous vein graft interventions is associated with significantly more in-hospital hemorrhagic/vascular events than controls in the firm's PRIDE trial

Embolic Protection Competition Fueled By Next-Generation Devices

Rapid-exchange versions of Possis Medical's AngioJet XMI and XVG catheters will make the thrombectomy device line a more attractive option for cath labs in the U.S. and abroad, the firm predicts

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel